Hikma Pharmaceuticals USA Inc. secured FDA approval to manufacture the generic form of Oxymorphone Hydrochloride, an oral analgesic, providing a cost-effective alternative to branded formulations. This regulatory clearance opens the market for direct competition, positioning the company to capture additional sales within the opioid analgesic segment.